1 / 54

臨床生化 TDM and Clinical Toxicology

臨床生化 TDM and Clinical Toxicology. 賴滄海 教授 01-11-2008. `. Reasons for Therapeutic Drug Monitoring Serious consequences for Overdose Small therapeutic index (LD 50 /ED 50 ) Poor correlation between dose and circulation concentration and therapeutic or toxic effects.

brinly
Download Presentation

臨床生化 TDM and Clinical Toxicology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 臨床生化TDM and Clinical Toxicology 賴滄海 教授 01-11-2008

  2. ` • Reasons for Therapeutic Drug Monitoring • Serious consequences for Overdose • Small therapeutic index (LD50/ED50) • Poor correlation between dose and circulation concentration and therapeutic or toxic effects

  3. There is a change of patient’s physiological states that may affect circulating drug concentration • Drug interaction may be occurring • TDM helps in monitoring patient compliance.

  4. Digoxin: • Absorption of orally administered digoxin is variable. 25% protein bound. Sequestered in muscle cells(15-30 times greater than plasma). T1/2 is 38 hours. • Range:0.8 to 2.0 ng/mL

  5. Digoxin: • Toxicity:Nausea, vomiting, visual disturbance, premature, ventricular contraction(PVC)and AV node blockage. • Interference:Low potassium, Magnesium, Hypothyroidism potentiate digoxin action. • Elimination:Kidney, liver . • Determined by immunoassay. DLIS cause false positive result.

  6. Lidocaine: • Administered IV. 70﹪protein bound. • Range:1.5 to 4.0μg/mL • Toxicity:CNS depression, Seizure, severe decrease in blood pressure and cardiac output. • Elimination:Metabolized in Liver(first pass)to MonoEthylXylidide(MEGX), which is toxic but without therapeutic activity.

  7. Quinidine: • Absorption of orally administered quinidine sulfate is complete. Quinidine gluconate is a slow releasing formulation. 70﹪protein bound. • Range:2 to 5 μg/mL • Toxicity:Nausea, vomiting, abdominal discomfort, premature, ventricular contraction(PVC)and AV node blockage. • Elimination: Liver

  8. Procanamide: • Absorption of orally administered drug is complete. 20﹪protein bound. • Range:4 to 8 μg/mL • Toxicity:Myocardial depression and arrhythmia. • Elimination:Liver metabolism to N-Acetyl procanamide(active metabolite)and Kidney filtration.

  9. Disopyramide: • Absorption of orally administered drug is complete. Protein binding is highly variable. • Range:3 to 5 μg/mL • Toxicity:Dry mouth, constipation(4.5 μg/mL). Bradicardia, AV node blockage(>10 μg/mL) • Elimination:Kidney, liver.

  10. Antibiotics Aminoglycosides:Amikacin, Gentamicin, Kanamycin, Tobramycin. • Administered IV or IM. Effective against gram-negative bacteria. • Toxicity:Orotoxic, disruption of inner ear cochlear and vestibular membranes. • Nephrotoxic, impair the function of proximal tubules of the kidney. • Elimination:Kidney.

  11. Vacomycin: • Administered IV. Protein binding is highly variable. Effective against gram-positive cocci and bacilli. • Range:5 to 10 μg/mL • Toxicity:Red-man syndrome, nephrotoxicity and orotoxicity. • Elimination:Kidney.

  12. Antiepileptic drugs: Phenobarbital, primidone • Absorption of orally administered drug is slow and complete. Protein binding is 50﹪. Long half-life. • Range:15 to 40 μg/mL • Toxicity:Drowsiness, fatigue, reduced mental capacity. • Elimination:Liver(inducer of MFO)and kidney.

  13. Phenytoin, Fosphenytoin • Absorption of orally administered drug is variable and incomplete. Protein binding is 87﹪to 97﹪. • Range:10 to 20 μg/mL • Toxicity:Initiation of seizure. • Hirsutism, gingival hyperplasia, vitamine D and folate deficiency. • Elimination:Kidney(zero order kinetics)

  14. Valproic Acid: • Absorption of orally administered drug is complete. Protein binding is 93﹪. • Range:50 to 120 μg/mL • Toxicity:Nausea, lethargy, weigh gain, pancreatitis, hyperammonemia and hallucinations. • Elimination:Liver metabolism.

  15. Carbamazepine: • Absorption of orally administered drug is variable. Protein binding is 70﹪to 80﹪. • Range:4 to 12 μg/mL • Toxicity:rash, leucopenia, nausea, vertigo, febrile reactions, aplastic anemia. • Elimination:Liver(inducer of enzyme)

  16. Psychoactive drugs Lithium • Absorption of orally administered drug is complete. • Range:0.8 to 1.2 μg/mL • Toxicity:Apathy, lethargy, speech difficulties and muscle weakness(1.2 to 2.0 mmole/L). Muscle rigidity, seizure and coma(>2 mmole/L) • Elimination:Kidney. • Analyzed with ISE, Flame emission photometry or AAS.

  17. Tricyclic antidepressants Impiramine, amitriptyline and active metabolites, doxepin. • Absorption of orally administered drug is variable. Protein binding is 85﹪to 95﹪. • Toxicity:Drowsiness, constipation, blurred vision, memory loss(2X upper limit). Seizure, cardiac arrhythmia and unconsciousness. • Elimination:Liver.

  18. Bronchodilators Theophylline • Absorption of orally administered drug is variable. Protein binding is 50﹪. • Range:10 to 20 μg/mL • Toxicity:Nausea, vomiting and diarrhea. Cardiac arrhythmia, seizure(>30 μg/mL) • Elimination:Kidney and liver.

  19. Immunosuppressive drugs Cyclosporine • Absorption of orally administered drug is variable(5﹪to 50﹪). Sequestered in cells. • Range:100-300 ng/mL • Toxicity:Renal tubular and glomerular dysfunction, hypertension. • Elimination:Liver. • Determined with immunoassays. Whole blood is the specimen of choice.

  20. The categories with the largest number of deaths are as follows:

  21. Salicylate • Aspirin (Acetylsalicylic acid) has analgesic, antipyretic and antiinflammatory properties. Therapeutic concentration: analgesic-antipyretic (lower than 60 mg/L) anti-inflammatory (150 to 300 mg/L) Aspirin interferes with platelet aggregation and thus prolongs bleeding times.

  22. Pharmacologic effect of salicylates • Stimulate central respiratory center • Uncoupling of oxidative phosphorylation • Enhance anaerobic glycolysis, Inhibite Kreb’s cycle and transaminase enzyme. • Respiratory alkalosis predominates in children over age 4 and in adults.

  23. Respiratory alkalosis (19%) • Metabolic acidosis (15%) • Combined (61%) motality was associated with acidemia

  24. Fig.25-13. Nomogram for estimating the severity of acute salicylate intoxication.(From Done, A.K.:salicylate intoxication: Significance of measurements of salicylate in blood in cases of acute ingestion. Pediatrics, 26:800, 1960. Reproduced by permission of Pediatrics.)

  25. Symptoms of salicylate intoxication • Tinnitus (耳鳴) • Diaphoresis (出汗) • Hyperthermia • Hyperventilation • Nausea, vomiting • Acid-base disturbances • CNS effects lethargy, disorientation, coma and seizures.

  26. Treatment • Ipecac to induce vomiting • Correction of acid-base and electrolyte imbalance, activated charcoal to prevent absorption • Hemodialysis

  27. Screening Assay for Acetaminophen and Salicylate • Acetaminophen After acid hydrolysis, the sample was reacted with o-cresol in basic solution to show blue color. • Salicylate Salicylates reacted with Ferric chloride solution to produce a violet color reaction. (Interferant: Diflunisal, labetalol, keto acids)

  28. Methemoglobin • Less than 1.5%of total hemoglobin in normal blood • Caused by methhemoglobin reductase deficiency or ingestion of nitrites, nitrates, phenacetin, phenazopyridine, sulfonamides, sulfones, aniline dyes. • Determined spectrophotometrically at 630 nm

  29. Alcohols • Ethanol • Methanol • Ethyleneglycol • Isopropylalcohol

  30. Effects of Ethanol • Cardiovascular system—Increase high-density lipoprotein • Central nervous system-CNS depression (Respiratory center, coma, death) • Gastrointestinal tract-Stimulate the production of gastric juices • Kidney-Diuretics ( Inhibit the secretion of ADH) • Liver-Fatty liver,Cirrhosis • Fetal alcohol syndrome

  31. Determination of Ethanols • Enzymatic • Headspace-GC • Breath-testing device (amount of ethanol in 1mL of blood equals to 2100mL of breath air) Henry’s law

  32. Ethyleneglycol 資料來源: 2007年5月7日自由時報

  33. Carbon Monoxide

  34. Lithium Use to treat manic-depressive illness. It enhances reuptake of neurotransmitters, thus produces sedating effect on the CNS • Toxicity apathy, sluggishness, drowsiness, lethargy, speech difficulties, irregular tremors, muscle weakness, ataxia, epileptic seizures. Determined with ISE or Atomic Absorption Spectrometry, Flame emission photometry

More Related